PSMA PET/CT–derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617

Radiology 2026 Open access

Read full text
Authors: Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, Andrei Gafita, Heather H. Cheng, Jessica E. Hawley, Ruben Raychaudhuri, Hiba Khan, Rajitha Sunkara, Andrew C. Hsieh, P. Grivas, B. Montgomery
+7 more Todd Yezefski, P Nelson, Evan Y. Yu, Michael T. Schweizer, Delphine L. Chen, Roman Gulati, Amir Iravani
DOI: 10.1148/radiol.250649
Cited by: 2
References: 20

Abstract

Incorporating prostate-specific membrane antigen (PSMA) PET/CT–derived total tumor volume with existing prediction models for overall survival, progression-free survival, and biochemical response to 177 Lu-PSMA-617 improved their discriminatory ability.

Fields of Study & Subjects

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Radiopharmaceutical Chemistry and Applications

Publication details

Journal / source
Radiology
Publisher
Radiological Society of North America (RSNA)
Volume
318
Issue
3
Pages
e250649–e250649
Publication date
1 March 2026
Language
EN